Editing Paroxetine (section)

===Suicide===
Like other antidepressants, paroxetine may increase the risk of suicidal thinking and behaviour in people under the age of 25.<ref>{{cite web|url=https://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/UCM161646.pdf |title=Medication Guide About Using Antidepressants in Children and Teenagers |archive-url=https://web.archive.org/web/20160311075028/http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/UCM161646.pdf |archive-date=11 March 2016 |url-status=live |publisher=FDA}}</ref><ref>{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm |title=FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards for Children Treated With Antidepressant Medications |website=[[Food and Drug Administration]] |archive-url=https://web.archive.org/web/20170118093030/http://www.fda.gov/newsevents/newsroom/pressannouncements/2004/ucm108363.htm |archive-date=January 18, 2017 |date=October 15, 2004 |url-status=dead}}</ref> The [[Food and Drug Administration|FDA]] conducted a statistical analysis of paroxetine clinical trials in children and adolescents in 2004 and found an increase in suicidality and ideation as compared to placebo, which was observed in trials for both depression and anxiety disorders.<ref name=FDA1>{{cite web|url=https://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf |title=Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality |access-date=27 January 2009 |vauthors=Hammad TA |date=16 August 2004 |website=Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Pediatric Advisory Committee. 13–14 September 2004. Briefing Information. |publisher=FDA |page=30 |archive-url=https://web.archive.org/web/20080625161255/https://www.fda.gov/OHRMS/DOCKETS/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf |archive-date=25 June 2008 |url-status=live}}</ref> In 2015, a paper published in ''[[The BMJ]]'' that reanalysed the original case notes argued that in [[Study 329]],<ref name="pmid11437014">{{cite journal | vauthors = Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP | title = Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial | journal = Journal of the American Academy of Child and Adolescent Psychiatry | volume = 40 | issue = 7 | pages = 762–772 | date = July 2001 | pmid = 11437014 | doi = 10.1097/00004583-200107000-00010 | s2cid = 2125130 }}</ref> assessing paroxetine and [[imipramine]] against placebo in adolescents with depression, the incidence of suicidal behavior had been under-reported and the efficacy exaggerated for paroxetine.<ref name="pmid26376805">{{cite journal | vauthors = Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E | title = Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence | journal = BMJ | volume = 351 | pages = h4320 | date = September 2015 | pmid = 26376805 | pmc = 4572084 | doi = 10.1136/bmj.h4320 }}</ref><ref>{{cite journal|vauthors=Godlee F |author-link=Fiona Godlee |title=Study 329 |journal=BMJ |volume=351 |page=h4973 |date=17 September 2015 |doi=10.1136/bmj.h4973 |doi-access=free}}</ref><ref name="pmid26377109">{{cite journal | vauthors = Doshi P | title = No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility | journal = BMJ | volume = 351 | pages = h4629 | date = September 2015 | pmid = 26377109 | doi = 10.1136/bmj.h4629 | s2cid = 44921667 }}</ref><ref name="pmid26377210">{{cite journal | vauthors = Henry D, Fitzpatrick T | title = Liberating the data from clinical trials | journal = BMJ | volume = 351 | pages = h4601 | date = September 2015 | pmid = 26377210 | doi = 10.1136/bmj.h4601 | s2cid = 41871189 }}</ref><ref>{{cite web| vauthors = Boseley S |url= https://www.theguardian.com/science/2015/sep/16/seroxat-study-harmful-effects-young-people |title=Seroxat study under-reported harmful effects on young people, say scientists |work=The Guardian |date=16 September 2015 |access-date=16 December 2016 |archive-url=https://web.archive.org/web/20160527025002/https://www.theguardian.com/science/2015/sep/16/seroxat-study-harmful-effects-young-people |archive-date=27 May 2016 |url-status=live}}</ref>